HCPLive
The ACG Annual Scientific Meeting and Postgraduate Course

ACG 2011: Challenging Issues in Ulcerative Colitis Therapy - Adherence and Quality of Life [Podcast]

Raymond Cross, MD, associate professor of medicine and director of the inflammatory bowel disease program at the University of Maryland School of Medicine, describes challenges with adherence to therapy and discusses methods to improve quality of life.


Most Popular

Recommended Reading

The explosion in new drugs to treat hepatitis C is leading to predictions the viral infection will no longer be a major health problem. But before that can happen, much has to be done in the realm of public health, researchers said April 25 at the International Liver Congress in Vienna, Austria.
Natalizumab, a drug typically used to treat multiple sclerosis and Crohn’s disease, has been shown to be effective in treating animal models of HIV.
The assumption used to be that after a liver transplant patients would need to take immunosuppressive drugs for years, even for life. A team of German researchers say that for about half of adult patients, that is no longer true.
As good news about new treatments for hepatitis C infections continues to dominate the 2015 International Liver Congress, Texas researchers today reported more success with sofosbuvir and daclatasvir.
$vAR$